HC Wainwright Analysts Decrease Earnings Estimates for Geron

Geron Co. (NASDAQ:GERN) – Stock analysts at HC Wainwright reduced their Q3 2025 earnings estimates for Geron in a research report issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter, down from their prior estimate of ($0.02). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.04) EPS.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $39.60 million for the quarter, compared to the consensus estimate of $49.88 million. During the same period in the previous year, the firm posted ($0.07) earnings per share. The firm’s revenue was up 12927.3% on a year-over-year basis.

Several other analysts also recently commented on the stock. Stifel Nicolaus decreased their target price on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Barclays reissued an “overweight” rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. Scotiabank downgraded shares of Geron from a “sector outperform” rating to a “sector perform” rating and decreased their target price for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $5.00 target price on shares of Geron in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Geron currently has an average rating of “Moderate Buy” and an average price target of $5.06.

Geron Stock Performance

Shares of GERN opened at $1.20 on Monday. The company’s 50 day moving average price is $1.47 and its 200 day moving average price is $2.69. Geron has a 52 week low of $1.17 and a 52 week high of $5.34. The company has a market capitalization of $764.30 million, a PE ratio of -3.75 and a beta of 0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Institutional Trading of Geron

Several large investors have recently modified their holdings of GERN. Vestal Point Capital LP boosted its holdings in shares of Geron by 947.6% during the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock worth $38,940,000 after buying an additional 9,950,000 shares during the period. Braidwell LP bought a new stake in shares of Geron during the 4th quarter worth $24,802,000. Boxer Capital Management LLC bought a new stake in shares of Geron during the 4th quarter worth $21,240,000. Woodline Partners LP boosted its holdings in shares of Geron by 64.6% during the 4th quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock worth $41,019,000 after buying an additional 4,549,031 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Geron by 20.0% during the 4th quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock worth $95,769,000 after buying an additional 4,516,615 shares during the period. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.